35 results
8-K
EX-99.1
LIANY
LianBio
13 Nov 23
LianBio Reports Third Quarter 2023 Financial Results and Provides Corporate Update
4:17pm
in 2022 and was partially offset by higher development activities to support clinical trials in 2023.
General & Administrative Expenses
General … and was partially offset by lower expenses for legal, consulting and accounting services.
Net Loss
Net loss was $24.0 million for the third quarter
8-K
EX-99.2
LIANY
LianBio
30 Oct 23
LianBio Announces Topline Results from Phase 3 LIBRA Trial of
4:16pm
offset by the reversal of general and administrative expenses attributable to mavacamten in the year ended December 31, 2021, which included
8-K
EX-99.1
ifhsod935u02
14 Aug 23
LianBio Reports Second Quarter 2023 Financial Results and Provides Corporate Update
4:11pm
8-K
EX-99.1
zlcyji
11 May 23
LianBio Reports First Quarter 2023 Financial Results and Provides Corporate Update
4:23pm
8-K
EX-99.1
utvbh9sfv8xp27f
10 Nov 22
LianBio Reports Third Quarter 2022 Financial Results and Provides Corporate Update
4:16pm
8-K
EX-99.1
mzlth rsgit71
11 Aug 22
LianBio Reports Second Quarter 2022 Financial Results and Provides Corporate Update
4:30pm
8-K
EX-99.1
vlwr 23psr0ka4
12 May 22
LianBio Reports First Quarter 2022 Financial Results and Provides Corporate Update
9:15am
10-K
zmdvyc9ur pvij
31 Mar 22
Annual report
8:55am
10-Q
weujnhu heqk4jv36m
9 Dec 21
Quarterly report
5:24pm
424B4
q3jrp 81gw
2 Nov 21
Prospectus supplement with pricing info
4:02pm